Rubicon Research IPO: A Key Analysis

• Strong investor interest drives high subscription rates for Rubicon Research.
• Non-Institutional Investors showed the biggest demand, oversubscribing significantly.
• Retail investors also showed considerable interest in the IPO offering.
• Grey market premium indicates strong investor confidence in the stock.
• The IPO aims to raise funds for strategic growth and debt repayment.
• Shares are expected to list on the NSE and BSE soon.

Rubicon Research, a pharmaceutical company, is nearing the end of its initial public offering (IPO) on October 13, 2025. The three-day bidding period has seen significant interest from investors. Currently, 437.16 million shares have been bid for, compared to the available 16.45 million, resulting in an impressive subscription rate of approximately 27.78 times.

Non-Institutional Investors were the biggest drivers of demand, subscribing their allocated quota 60.64 times – a massive oversubscription. Retail investors also showed robust interest, subscribing at 21.7 times, while Qualified Institutional Buyers (QIBs) subscribed at 13.46 times and employees at 11.04 times.

The grey market premium, observed at ₹580, reflecting a 19.6% premium over the IPO price of ₹485, suggests investors anticipate a positive performance for the stock. This indicates strong confidence among traders.

Analysts like Arihant Capital recommend subscription, and Kabir Sharma from SMIFS advises a long-term investment strategy due to Rubicon’s leadership in the US market, specialized products, and growing international presence.

Rubicon Research plans to raise ₹1,377.5 crore through issuing 10.3 million equity shares and offering an additional 18.1 million shares for sale. The IPO price range is ₹461 to ₹485, with a lot size of 30 shares. Investors can bid with a minimum of one lot, requiring an investment of ₹14,550 at the higher end.

The successful allottees will receive their shares by Wednesday, October 15, 2025, and the shares are expected to list on the NSE and BSE on Thursday, October 16, 2025. Axis Capital, IIFL Capital Services, JM Financial, and SBI Capital Markets are involved in managing the IPO process, and MUFG Intime India is the registrar.

Ultimately, the success of the Rubicon Research IPO hinges on market conditions and the company’s future performance.